IgG4-Related Disease: A Retrospective Chinese Study of Features and Treatment Response of 98 Patients Including 4 Rare Cases

Abstract

The features and treatment of 98 Chinese patients with immunoglobulin G4 (IgG4)-related disease (IgG4-RD) referred to a single tertiary referring centre were reviewed. Patients diagnosed with IgG4-RD according to the comprehensive diagnostic criteria (CDC) were included in the retrospective study from May 2012 to March 2019. We collected data on clinical, laboratory, imaging, histological features and treatment. Totally, 98 patients with IgG4-RD were enrolled. The common clinical manifestations included abdominal pain, salivary gland swelling and lymphadenopathy. 51% of the patients had multiple organs involvement. Lymph nodes, pancreas and salivary glands were most commonly involved. Four rare sites including ulna, cerebellum, scalp, and mammary gland were found. The serum IgG4 level was increased by 85.7%. The serum IgG4 level was positively correlated with the number of involved organs, IgG and IgG4/IgG. Low C3 and C4 levels were observed in 37.5% and 12.2% patients respectively, and all patients with kidney involvement had hypocomplementemia. A total of 54 patients underwent tissue biopsies, and 55.6%, 31.5% and 11.1% cases were diagnosed as definite, probable and possible IgG4-RD, respectively. Eighty-eight patients received glucocorticoids (GCs) therapy. Five patients underwent radical surgery to remove the lesion. 73% of them presented a complete or partial remission. IgG4-RD is a systemic fibroinflammatory disease with involvement of multiple organs throughout the body including some rare sites. Most IgG4-RD patients had increased serum IgG4 levels and patients with kidney involvement showed hypocomplementemia. GCs therapy is effective. More research is needed to provide a more reliable basis for the diagnosis and treatment of patients.

Keywords

immunoglobulin G4-related disease / clinical features / Immunoglobulin G4 / hypocomplementemia / glucocorticoid

References

[1] StoneJH, ZenY, DeshpandeV. IgG4 related disease. N Engl J Med, 2012, 366(6): 539-551

[2] UmeharaH, OkazakiK, MasakiY, et al.. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol, 2012, 22(1): 21-30

[3] RotondiM, CarboneA, CoperchiniF, et al.. Diagnosis of Endocrine Disease: IgG4-related thyroid autoimmune disease. Eur J Endocrinol, 2019, 180(5): R175-R183

[4] LeeCW, Ronnekleiv-KellyS. Autoimmune Diseases of the Biliary Tract: A Review. Surg Clin North Am, 2019, 99(2): 185-201

[5] DetigerSE, KarimAF, VerdijkRM, et al.. The treatment outcomes in IgG4-related orbital disease: a systematic review of the literature. Acta Ophthalmol, 2019, 97(5): 451-459

[6] YamamotoM, TakahashiH, OharaM, et al.. A new conceptualization for Mikulicz’s disease as an IgG4-related plasmacytic disease. Mod Rheumatol, 2006, 16(6): 335-340

[7] KhosroshahiA, WallaceZS, CroweJL, et al.. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol, 2015, 67(7): 1688-1699

[8] KamisawaT, ShimosegawaT, OkazakiK, et al.. Standard steroid treatment for autoimmune pancreatitis. Gut, 2009, 58(11): 1504-1507

[9] IaccarinoL, TalaricoR, ScirèCA, et al.. IgG4-related diseases state of the art on clinical practice guidelines. RMD Open, 2019, 4(Suppl 1): e000787

[10] TopiwalaK, HamptonC, BolandC, et al.. Neurologic IgG4-Related Disease. Neurohospitalist, 2019, 9(2): 118-119

[11] García-CurdiF, Lois-OrtegaY, Gonzales-SejasAG, et al.. IgG4 related disease with exclusive sinonasal involvement: A case report and literature review. Rev Esp Patol, 2019, 52(2): 125-129

[12] KottahachchiD, ToplissDJ. Immunoglobulin G4-Related Thyroid Diseases. Eur Thyroid J, 2016, 5(4): 231-239

[13] KamisawaT, ZenY, NakazawaT, et al.. Advances in IgG4-related pancreatobiliary diseases. Lancet Gastroenterol Hepatol, 2018, 3(8): 575-585

[14] YamadaK, YamamotoM, SaekiT, et al.. New clues to the nature of immunoglobulin G4-related disease: a retrospective Japanese multicenter study of baseline clinical features of 334 cases. Arthritis Res Ther, 2017, 19(1): 262-272

[15] LinW, LuS, ChenH, et al.. Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. Rheumatology (Oxford), 2015, 54(11): 1982-1990

[16] InoueD, YoshidaK, YonedaN, et al.. IgG4-related disease: dataset of 235 consecutive patients. Medicine (Baltimore), 2015, 94(15): e680

[17] Fernandez-CodinaA, Martinez-ValleF, PinillaB, et al.. IgG4-Related Disease: Results From a Multicenter Spanish Registry. Medicine (Baltimore), 2015, 94(32): e1275

[18] EbboM, DanielL, PavicM, et al.. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore), 2012, 91(1): 49-56

[19] CampochiaroC, RamirezGA, BozzoloEP, et al.. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. Scand J Rheumatol, 2016, 45(2): 135-145

[20] ChenH, LinW, WangQ, et al.. IgG4-related disease in a Chinese cohort: a prospective study. Scand J Rheumatol, 2014, 43(1): 70-74

[21] SatoY, TakeuchiM, TakataK, et al.. Clinicopathologic analysis of IgG4-related skin disease. Mod Pathol, 2013, 26(4): 523-532

[22] YokoeT, HayashidaT, KikuchiM, et al.. IgG4-related mastopathy: A case report and literature review. Clin Case Rep, 2018, 6(8): 1549-1553

[23] KhosroshahiA, WallaceZS, CroweJL, et al.. Second international symposium on IgG4-related disease. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol, 2015, 67(7): 688-699

[24] ShirakashiM, YoshifujiH, KodamaY, et al.. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep, 2018, 8(1): 10 262